MedPath

A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.25/750 mg in Healthy Male Volunteers

Phase 1
Completed
Conditions
Diabetes Mellitus, Type II
Interventions
Drug: Duvie Tab. 0.5mg, Glucodaun OR Tab. 750mg
Drug: CKD-395 0.25/750mg
Registration Number
NCT02627027
Lead Sponsor
Chong Kun Dang Pharmaceutical
Brief Summary

This study is a randomized, open-label, single dose, 2-way crossover study to compare the pharmacokinetic characteristics of CKD-395 0.25/750 mg in healthy male volunteers.

Detailed Description

To healthy male subjects of twenty six(26), following treatments are administered dosing in each period fed condition(high fat meals) and wash-out period is a minimum of 7 days.

Treatment A(Reference Drug): DuvieTM Tab. 0.5mg 1T + Glucodaun OR Tab. 750mg 2T Treatment B(Test Drug): CKD-395 0.25/750mg Tab. 2T Pharmacokinetic blood samples are collected up to 48hrs. Safety and pharmacokinetic are assessed.

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
26
Inclusion Criteria
  1. Healthy man older than 19 years at the time of screening.
  2. BMI more than 17.5kg/m2 and less than 30.5kg/m2 and weight more than 55kg
  3. Subject without congenital or chronic diseases and no psychotic symptoms or findings from the medical examination.
  4. Suitable subject who is determined by laboratory tests such as hematology tests,blood chemistry, urinalysis test according to the characteristics of the drug and screening tests such as ECG test.
  5. Subject who fully understand the clinical trials after in-depth explanation given prior to the clinical study, decided to join the clinical trials by their will and signed consent form which approved by Chonbuk National University Hospital IRB.
  6. Subjects who are able to comply with all scheduled visits, laboratory tests and other procedures.
Read More
Exclusion Criteria
  1. Subjects who has a history of blood, kidneys, endocrine, respiratory, gastrointestinal, urinary, cardiovascular, hepatic, psychiatric, neurological or allergic diseases that is clinically significant (Except untreated asymptomatic seasonal allergies at the time of administration)
  2. Subjects who has a history of gastrointestinal disease or gastrointestinal surgery which can affect drug absorption.
  3. Subjects who show AST or AST > 2 times upper limit of normal range.
  4. Subjects who drink Alcohol > 210g/week within 6 months prior to the screening.
  5. Subjects who take the medication involved in other clinical trials or bioequivalence tests within three months before the first dose medication characters.
  6. Subjects who show Systolic Blood Pressure ≥ 140 mmHg or Diastolic Blood Pressure ≥ 90 mmHg at screening.
  7. Subjects who have history of alcohol or drug abuse, within 1 year
  8. Subjects who treated with metabolizing enzyme inducers or inhibitors such as barbitals within 30days prior to the first dosing.
  9. Smoker ( ≥ 20cigarettes/day)
  10. Subjects who takes ETC or OTC medicine within 10days before the first IP administration.
  11. Subjects who do the whole blood donation within two months or component blood donation within 1month prior to the first dosing.
  12. Subjects who can increase risk due to clinical test and administration of drugs or has Severe grade / chronic medical, mental condition or abnormal laboratory result that may interfere with the analysis of test results.
  13. Patients with hypersensitivity to lobeglitazone or any other thiazolidinediones ( Rosiglitazone, Rioglitazone) and to Metformin or any other biguanides
  14. Patients with severe heart failure or congestive heart failure of needing drug therapy
  15. Patients with liver disease
  16. Patients with severe renal disease
  17. Patients with diabetes mellitus with ketoacidosis, diabetes coma and prior
  18. Patients before or after surgery, with severe infections, severe trauma
  19. Subjects with hereditary diseases of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
  20. Patients with renal disease or renal failure caused by cardiovascular collapse, acute myocardial infarction, sepsis (Serum creatinine ≥ 1.5mg/dL or abnormal creatine clearance)
  21. Patients who had a test to injecting radioactive iodine in vein
  22. Patients with severe infections or severe traumatic whole body injuries
  23. Patients with undernourishment condition or starvation state or hyposthenia or hypopituitarism, or hypoadrenalism
  24. Patients with respiratory failure, or stomach disease
  25. Subjects who is not able to intake high fat meals
  26. Subjects who is not able to comply with guidelines described in the protocol.
  27. Subjects who is determined by investigator's decision as unsuitable for clinical trial participation.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
RT groupCKD-395 0.25/750mgR: Reference drug(Duvie Tab. 0.5mg 1T, Glucodaun OR Tab. 750mg 2T) T: Test drug(CKD-395 0.25/750 mg 2T)
RT groupDuvie Tab. 0.5mg, Glucodaun OR Tab. 750mgR: Reference drug(Duvie Tab. 0.5mg 1T, Glucodaun OR Tab. 750mg 2T) T: Test drug(CKD-395 0.25/750 mg 2T)
TR groupDuvie Tab. 0.5mg, Glucodaun OR Tab. 750mgT: Test drug(CKD-395 0.25/750 mg 2T) R: Reference drug(Duvie Tab. 0.5mg 1T, Glucodaun OR Tab. 750mg 2T)
TR groupCKD-395 0.25/750mgT: Test drug(CKD-395 0.25/750 mg 2T) R: Reference drug(Duvie Tab. 0.5mg 1T, Glucodaun OR Tab. 750mg 2T)
Primary Outcome Measures
NameTimeMethod
AUClast of LobeglitazoneLobeglitazone: 0(Pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48hrs
AUClast of metforminMetformin: 0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24 and 48hrs
Cmax of LobeglitazoneLobeglitazone: 0(Pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48hrs
Cmax of Lobeglitazone MetforminMetformin: 0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24 and 48hrs
Secondary Outcome Measures
NameTimeMethod
AUCinf of LobeglitazoneLobeglitazone: 0(Pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48hrs
t1/2 of MetforminMetformin: 0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24 and 48hrs
Vd/F of LobeglitazoneLobeglitazone: 0(Pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48hrs
Vd/F of MetforminMetformin: 0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24 and 48hrs
Tmax of LobeglitazoneLobeglitazone: 0(Pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48hrs
CL/F of LobeglitazoneLobeglitazone: 0(Pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48hrs
AUCinf of MetforminMetformin: 0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24 and 48hrs
CL/F of MetforminMetformin: 0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24 and 48hrs
Tmax of MetforminMetformin: 0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24 and 48hrs
t1/2 of LobeglitazoneLobeglitazone: 0(Pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48hrs

Trial Locations

Locations (1)

Chonbuk National University Hospital

🇰🇷

Jeonju-si, Jeollabuk-do, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy